secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001493152-24-000578
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs appoints Jed Latkin as COO; CFO Robert Morse returns to Controller role
--------------------------------------------------------------------------------

- Jed Latkin named COO effective Jan 1, 2024; base salary $350,000, sign-on bonus $80,000.
- Latkin receives inducement stock options for 500,000 shares at $6.00, vesting over 3 years (25% immediate).
- Robert Morse ceases as CFO and resumes Controller role effective Jan 1, 2024, reporting to COO.
- Press release highlights 2024 growth plans for Nebula Genomics, Pharmaloz Manufacturing, and BE-SMART test commercialization.
- Latkin previously served as CEO of Navidea and has 28+ years in finance and biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224000578/0001493152-24-000578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224000578/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-000578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer